Filing Flows › Castle Biosciences (CSTL) › Non-Dermatologic revenue
Castle Biosciences (CSTL) Non-Dermatologic revenue by quarter
Castle Biosciences' Non-Dermatologic revenue was $55.0M in Q3 2026 (third quarter 2026), +0.3% from Q2 2026. Over the last 7 quarters it ranged from $25.0M (Q1 2025) to $55.0M (Q3 2026).
| Quarter | Non-Dermatologic revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $55.0M | +0.3% | +59% |
| Q2 2026 | $54.8M | +29% | +83% |
| Q1 2026 | $42.6M | +11% | +70% |
| Q4 2025 | $38.4M | +11% | — |
| Q3 2025 | $34.5M | +15% | — |
| Q2 2025 | $29.9M | +19% | — |
| Q1 2025 | $25.0M | — | — |
Q3 2026 at a glance
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Castle Biosciences' Non-Dermatologic revenue?
Castle Biosciences' Non-Dermatologic revenue was $55.0M in Q3 2026 (third quarter 2026), +0.3% from Q2 2026.
How has Castle Biosciences' Non-Dermatologic revenue changed?
Over the last 7 quarters it ranged from $25.0M (Q1 2025) to $55.0M (Q3 2026).